-
Last week, a large number of pharmaceutical companies were reduced by shareholders
Time of Update: 2022-12-30
js?cdnversion='+~(-new Date()/36e5)];This year's wave of reduction is sweeping the pharmaceutical circle, and a large number of listed pharmaceutical companies are announcing the reduction of shareholders or executives one after another, including WuXi AppTec, Inco Medical, Aotai Biologics, Huasen Pharmaceutical, Aviron and so on.
-
In 2023, these 20 blockbuster new drugs are expected to be approved in China
Time of Update: 2022-12-30
Since 2022, the international situation is severe and complex, the epidemic continues to progress, China's pharmaceutical industry has inevitably been affected, up to now, the State Medical Products
-
The price of raw materials for Lianhua Qingwen has skyrocketed, and ensuring production is the top priority!
Time of Update: 2022-12-30
According to the third quarterly report of 2022 released by Shijiazhuang Yiling Pharmaceutical Co. , Ltd. (Yiling Pharmaceutical, 002603), in the first three quarters, the company achieved operating
-
Pharmacopoeia: Guidelines for the determination of powder flowability published
Time of Update: 2022-12-30
The most common method for determining static rest angle can be classified based on the following two important experimental variables: The height of the powder through the "funnel" is fixed relative to the chassis, or its height can change with the formation of the cone.
-
Announcement of the State Food and Drug Administration on the Implementation of Electronic Declaration of Drug Registration Applications (No. 110 of 2022)
Time of Update: 2022-12-30
In order to improve the efficiency of drug review and approval, the State Food and Drug Administration has decided to implement electronic submission of application materials for drug registration, and the specific requirements are announced as follows:1.
-
6 varieties of more than 1 billion proprietary Chinese medicines lead the way and 38 exclusive varieties dominate the screen
Time of Update: 2022-12-30
Recently, the State Administration of Traditional Chinese Medicine issued the "Guidelines for Home Medicine Intervention for People Infected with the New Coronavirus Infection", and 60 proprietary Ch
-
The innovation and upgrading of medicine bag equipment has accelerated, and the development trend of automation and intelligence in the industry is obvious
Time of Update: 2022-12-30
Under the acceleration of innovation and upgrading of medicine bag equipment, the development trend of intelligence is obvious (Image source: Pharmaceutical Network) In this context, the industry generally believes that the domestic pharmaceutical packaging machine industry has both opportunities and challenges, and equipment suppliers need to keep up with the pace of the entire industry and accelerate the improvement of competitiveness.
-
MAH's implementation of the list of main responsibilities for drug quality has come, and the key personnel of pharmaceutical companies are trembling
Time of Update: 2022-12-30
1. What is the scope of MAH key personnel?1) The definition of key personnel in the current version of GMP in China in 2010: The key personnel of a pharmaceutical production enterprise shall be full-time personnel of the enterprise, at least including the person in charge of the enterprise, the person in charge of production management, the person in charge of quality management and the person in charge of quality authorization (Chapter 3 Institutions and Personnel Article 20).
-
In 2022, China's innovative drug license out transactions TOP10
Time of Update: 2022-12-30
On the evening of December 6, Akeso announced that it entered into a licensing transaction cooperation with Summit for overseas rights (the United States, Europe, Japan and Canada) for PD-1/VEGF bispecific antibodies (Ewosi, AK112) with a down payment of 500 million US dollars and a total amount of up to 5 billion US dollars, which has attracted widespread attention in the industry.
-
CDE issued four announcements, including "Technical Guidelines for Bioequivalence Research of Amphotericin B Liposomes for Injection"
Time of Update: 2022-12-30
The Drug Review Center of the State Food and Drug Administration issued the "Technical Guidelines for Bioequivalence Research of Amphotericin B Liposomes for Injection", "Technical Guidelines for Bio
-
Novo Nordisk Shanghai signed a contract with Shanghai Pharmaceutical Holdings The cooperation will achieve another breakthrough
Time of Update: 2022-12-30
Xiaping Zhou, Senior Vice President and President of Greater China, Novo Nordisk, said: "This investment is an important step for Novo Nordisk to realize the new layout of the 'dual center, three engines' whole industry chain, which will further strengthen the business capabilities of the trade and innovation center in Shanghai, support the development of Shanghai's pharmaceutical trade, and better serve Chinese patients.
-
Zhejiang Province Centralized Drug Procurement Results Announced (with List)
Time of Update: 2022-12-30
The data shows that the total sales scale of this collection and procurement varieties in public hospitals in Zhejiang Province in 2021 exceeded 300 million yuan (in terms of common names), involving bright prorelin injection, triptorelin injection, lactulose oral liquid and other large clinical varieties, Lizhu, Shisi Yao, Luoxin Pharmaceutical and other enterprises successfully broke through.
-
The market of more than 30 billion antithrombotic drugs is highly competitive, and 3 first generic drugs have been added during the year
Time of Update: 2022-12-30
These two products are antithrombotic drugs, of which clopidogrel aspirin tablets are the first imitation, and the sales scale of rivaroxaban tablets in China's three major terminal markets in 2021 exceeded 5 billion yuan.
-
【Q&A】SPI product questions and answers
Time of Update: 2022-12-30
Answer: It is recommended to use mannitol Mannogem®XL Opal and XL Ruby, which have high compressibility, high drug load, fast disintegration, low brittleness, good taste, can press out tablets with qualified hardness under various pressures, the dosage is smaller, and the cost is reduced.
-
Drug supply war under the epidemic: pharmaceutical factories do not stop production
Time of Update: 2022-12-30
From: Dandelion (ouryao. com) Finishing: Green to blue Recently, there has been a shortage of antipyretic and analgesic drugs such as ibuprofen in many places, in order to ensure the market supply of
-
Many pharmaceutical companies suspended! All trading was suspended due to abnormal fluctuations in the rise and fall
Time of Update: 2022-12-30
2 million in the same period in 2021; The net loss in the first quarter of 2022 was approximately RMB14.
2 million in the same period in 2021; The net loss in the first quarter of 2022 was approximately RMB14.
-
The double antibody research and development track is hot! Cinda and other nuggets exceed 200 billion market
Time of Update: 2022-12-30
Sales of anti-tumor and immunomodulatory agents in China's three major terminal markets in recent years (: million yuan)Source: Minai Grid Bureau database From the perspective of treatment categories, anti-tumor and immunomodulatory agents are the majority, and a total of 71 drugs are undergoing clinical research; There are 3 sensory system drugs, 2 blood and hematopoietic system drugs, 1 digestive system and metabolic drug, and 1 systemic anti-infective drug, all of which have entered the clinical trial stage.
-
Since December, many pharmaceutical companies have encountered setbacks in drug research and development
Time of Update: 2022-12-30
js?cdnversion='+~(-new Date()/36e5)];On December 19, AstraZeneca announced that the drug Imfinzi, as a monotherapy for patients with advanced non-small cell lung cancer, failed to achieve its primary goal of improving overall survival compared to platinum-based chemotherapy.
-
Another group of domestic and foreign pharmaceutical executives proposed to leave at the end of the year
Time of Update: 2022-12-30
On December 13, Chengdu Pilot announced that Mr. Wan Jinqiao, a senior manager and core technical personnel of the company, recently submitted a resignation application to the company due to personal reasons, and will no longer hold any position in the company after his resignation.
-
The pediatric proprietary Chinese medicine market continues to recover! Top 20 announced (with list)
Time of Update: 2022-12-30
Encouraged by favorable policies and the growth of market demand under the normalization of the epidemic, the terminal pediatric proprietary Chinese medicine market in China's public medical instituti
